Stoke (STOK) - Multiplikator Forward P/S
Stoke Therapeutics (STOK) is utilizing its oligonucleotide synthesis capacities to the maximum to adhere to trial schedules. The issuer's forward P/S helps filter out market noise, with the value holding at 60.40. Drug development is accelerating through AI modeling and automation. The business is anchored by the TANGO platform, which creates a closed therapeutic loop by managing gene expression.
Rincian metrik lan analitis perusahaan Stoke Corp (STOK)
- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Rasio Total Utang marang Ekuitas Stoke Therapeutics|STOK - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Stoke Therapeutics|STOK - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Stoke Corp|STOK - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Stoke Therapeutics|Likuiditas cepet stoketherapeutics.com
- data bathi bisnis lan rasio investasi:
STOK - Asil keuangan resik|Bathi sing dikarepake Stoke Therapeutics|STOK - Periode bali modal bisnis|Prakiraan rega marang bathi Stoke|STOK - Rasio nilai perusahaan marang wutah bathi|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Stoke Corp|STOK - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Stoke Therapeutics|STOK - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan stoketherapeutics.com|STOK - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Stoke Therapeutics
- informasi babagan volume dodolan lan pendapatan:
Analisis umum perusahaan:Stoke Therapeutics, Inc. STOK
For Stoke Therapeutics (STOK), which is developing breakthrough RNA therapy for Dravet syndrome, changes in the forward P/S ratio serve as an indicator of market expectations regarding pipeline commercialization. This multiple compares current market capitalization with projected revenue for future periods. It measures the premium for scientific potential, reflecting the value of each unit of expected sales. A decline in this metric may indicate an undervalued asset or increasing risks associated with the execution of clinical trials.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|Rega forward marang dodolan QGEN|Ionis Pharma - Multiplikator Forward P/S|RGEN - Multiplikator Forward P/S|Avidity Biosciences (RNA) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan CRSP (crisprtx.com)|WGS (GeneDx) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ultragenyx Pharmaceutical Inc. RARE|Multiplikator forward rega marang pendapatan BEAM (Beam Therapeutics Corp)|Multiplikator Forward P/S Sarepta Corp (SRPT)|Twist Bioscience - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake TXG (10xgenomics.com)|Intellia Therapeutics, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake BioLife Solutions Inc BLFS|WVE: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Maze Therapeutics Corp|Rasio rega marang prakiraan pendapatan Sionna Therapeutics Inc|primemedicine.com (PRME) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Taysha Gene Therapies, Inc. (TSHA)|Rasio kapitalisasi marang dodolan sing dikarepake uniQure NV|MeiraGTx PLC - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake RGNX (REGENXBIO Corp)|SLDB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ocugen.com|PacBio (PACB) - Rasio rega marang prakiraan pendapatan|Benitec Biopharma Inc (BNTC) - Multiplikator Forward P/S|DSGN (Design Pharma) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan RCKT (Rocket Corp)|Rasio rega marang prakiraan pendapatan 4D Molecular Therapeutics (FDMT)|lexeotx.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S KRRO (Korro Bio)|Multiplikator Forward P/S Editas Medicine Inc EDIT|SLN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake ProQR Therapeutics N.V. PRQR|CDXS (codexis.com) - Multiplikator forward rega marang pendapatan|SGMO: Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan Nautilus Biotechnology, Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Metagenomi Inc. MGX|Rasio rega marang prakiraan pendapatan Precision BioSciences, Inc. (DTIL)|Multiplikator Forward P/S generationbio.com (GBIO)|Multiplikator Forward P/S BOLD (Boundless Bio, Inc.)|Exicure Inc. (XCUR) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|IMNN: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan PHIO (Phio Pharmaceuticals)|MBIO (mustangbio.com) - Multiplikator forward rega marang pendapatan|RNAZ: Rasio rega marang pendapatan sing dikarepake|BNGO (Bionano Genomics Inc.) - Multiplikator Forward P/S|APDN: Rega forward marang dodolan|Multiplikator Forward P/S BLUE|IPA - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Omega OMGA|Rega forward marang dodolan OMIC|Regulus Therapeutics - Multiplikator Forward P/S|SYRS - Multiplikator Forward P/S|Telesis Bio (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON Pharmaceuticals Inc.)|UBX (Unity Bio) - Multiplikator Forward P/S
